befiradol
Small moleculeexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 9, 2021 (NCT05148884)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
HTR1A agonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccc(CNCC2(F)CCN(C(=O)c3ccc(F)c(Cl)c3)CC2)nc1- Mol. weight
- 393.87 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL45305 ↗
Also known as
- ((3-chloro-4-fluoro-phenyl)-(4-fluoro-4-((5-methyl-pyridin-2-ylmethyl)-amino)-methyl)piperidin-1-yl)-methadone
- befiradol
- befiradol
- befiradol
- f13640
- f 13640
- f-13640
- f-13640
- nlx-112
- nlx-112
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05148884 | Phase 2 | Nov 9, 2021 | ASC Torsplan, Clinical Trial Consultants AB, Michael J. Fox Foundation for Parkinson's Research, Neurolixis, PARKINSONS UK |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ASC Torsplan | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Clinical Trial Consultants AB | For profit | 1 | 0 | 1 | 2021 |
| Michael J. Fox Foundation for Parkinson's Research | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Neurolixis | For profit | 1 | 1 | 1 | 2021 |
| PARKINSONS UK | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1